How California Can Overcome Its Cannabis Challenges
Ryan Allway December 14th, 2018 Uncategorized California’s cannabis industry is projected to reach $5.1 billion by the end of 2019, according to BDS Analytics, but unexpected challenges have slowed progress. These challenges range from excessive regulations to sky-high taxation. Investors looking for opportunities in the state may want... Read more
Blockchain Technology Offers a Solution to Cannabis Quality Control
Ryan Allway December 14th, 2018 Exclusive, News, Top News The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, following the legalization of adult-use cannabis earlier this year. While early sales have been brisk, the industry faces key challenges with safety... Read more
Aleafia Health: A New LP with 22 Medical Clinics, 50K Patients and 98,000 kg Production
Ryan Allway December 14th, 2018 Exclusive, News, Top Story The Canadian cannabis market is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis nationwide. While many companies are focused on supplying the recreational market, the medical market may... Read more
Grown Rogue Moves into California’s $5 Billion Cannabis Market
Ryan Allway December 12th, 2018 Exclusive, News, Top Story California’s cannabis industry is the largest in the country with revenue expected to reach $5.1 billion by 2022, according to Arcview Market Research and BDS Analytics. With about 40 million residents and a long history of cannabis usage, the... Read more
Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets
Ryan Allway December 5th, 2018 Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study aims to show... Read more
FSD Pharma Congratulates Partner Canntab on Launch of Research Partnership with Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D.
– FSD Pharma to work with Canntab to create tablets for the clinical research study at its facility in Cobourg, Ontario, Canada – FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) (CSE:PILL) (TBF1.F) on the launch of a research partnership with... Read more
BLOCKStrain Brings Security, Scalability, and Transparency to Cannabis Supply Chain
Ryan Allway November 20th, 2018 Uncategorized The cannabis industry is experiencing massive growth, but the infrastructure behind the boom leaves a lot to be desired. Many cultivators are still using spreadsheets to track products across the supply chain, while regulators are struggling to find good ways to track... Read more
FSD Pharma Adds David Urban to Board Of Directors
Ryan Allway November 14th, 2018 TORONTO – November 14, 2018 – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors. Mr. Urban is an accomplished business and government relations executive.... Read more
BLOCKStrain Addresses Cannabis Diversion & Inversion Challenges
Ryan Allway October 29th, 2018 News, Press Releases, Top News The U.S. cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. At the same time, Deloitte believes... Read more
Entrepreneurs see Santa Cruz as fertile ground for cannabis startups
SANTA CRUZ — Entrepreneurs hoping to make it big in California’s new cannabis marketplace are planting roots in Santa Cruz County, looking to bring new meaning to the term “high tech.” Area initiatives include an online pot marketplace, a smart-growing solution that harnesses big data and an app that... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )